[8-K] Ocuphire Pharma, Inc. Common Stock Reports Material Event

Rhea-AI Filing Summary

Opus Genetics, Inc. reported that on August 13, 2025 it issued a press release announcing its financial results for the second quarter ended June 30, 2025. The press release is furnished as Exhibit 99.1 to this Current Report and the company also furnished a Cover Page Interactive Data File (Inline XBRL) as Exhibit 104.1. The filing states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to Section 18 of the Exchange Act or incorporated by reference except by specific reference in a later filing. The report shows Opus Genetics is a Delaware corporation and lists its common stock trading under the ticker IRD on Nasdaq. The document is signed by Dr. George Magrath, Chief Executive Officer.

Positive

• None.

Negative

• The 8-K does not include the actual financial figures for the quarter; readers must consult Exhibit 99.1 for substantive results.
• The filing explicitly states the press release is furnished, not filed, which limits Section 18 liability and may reduce direct legal incorporation of the release into future filings.

Insights

Financial Analyst

TL;DR: Routine disclosure of quarterly results; no financial figures included in this filing itself.

The 8-K notifies investors that the company issued a press release for Q2 2025 results and attaches that release as Exhibit 99.1. Crucially, the 8-K itself does not present any revenue, earnings, cash flow, or balance sheet numbers; it only furnishes the press release and Inline XBRL cover page. Because the release is "furnished, not filed," the company distances these disclosures from Section 18 liability. Investors must review Exhibit 99.1 for substantive financial metrics; absent those figures, this filing is a procedural disclosure rather than a standalone earnings report.

Corporate Governance Expert

TL;DR: Proper procedural filing; signature and exhibit indexing are in order but substantive detail is delegated to the press release exhibit.

The form identifies the press release and Inline XBRL cover page as exhibits and includes an authorized signature from the CEO, meeting Form 8-K procedural requirements. The explicit statement that the information is "furnished and shall not be deemed 'filed'" is standard governance language to limit incorporation by reference. This 8-K does not disclose management changes, material transactions, or detailed financial disclosures within the body of the filing; those items, if present, would need to appear in the press release or subsequent filings.

false000122862700012286272025-08-132025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

Opus Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-34079	11-3516358
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

8 Davis Drive Durham, NC		27713
(Address of principal executive offices)		(Zip Code)

(984) 884-6030

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value per share	IRD	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Opus Genetics, Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the second quarter ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference.

The information in this Item 2.02 of this Current Report on Form 8-K, and Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release, dated August 13, 2025.
104.1	Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 13, 2025	OPUS GENETICS, INC.
	By:	/s/ Dr. George Magrath
	Name:	Dr. George Magrath
	Title:	Chief Executive Officer

FAQ

What did Opus Genetics (IRD) disclose in this 8-K?

The filing states the company issued a press release announcing financial results for the quarter ended June 30, 2025, furnished as Exhibit 99.1.

Are the Q2 2025 financial figures included in the 8-K?

No. The 8-K notes the press release announces the results, but the filing itself does not include financial figures; those are in Exhibit 99.1.

Is the press release in this filing considered "filed" or "furnished"?

The company expressly states the press release and related information are furnished and not filed, so they are not subject to Section 18 of the Exchange Act.

Which exhibits are attached to this Current Report?

Exhibit 99.1 is the press release dated August 13, 2025, and Exhibit 104.1 is the Cover Page Interactive Data File (Inline XBRL).

Who signed the 8-K for Opus Genetics?

The filing is signed by Dr. George Magrath, Chief Executive Officer.